(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 40.19% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.4%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.41%.
Harrow's revenue in 2024 is $154,146,000.On average, 1 Wall Street analysts forecast HROW's revenue for 2024 to be $7,504,287,827, with the lowest HROW revenue forecast at $7,504,287,827, and the highest HROW revenue forecast at $7,504,287,827. On average, 1 Wall Street analysts forecast HROW's revenue for 2025 to be $10,982,680,827, with the lowest HROW revenue forecast at $10,982,680,827, and the highest HROW revenue forecast at $10,982,680,827.
In 2026, HROW is forecast to generate $15,191,667,644 in revenue, with the lowest revenue forecast at $15,191,667,644 and the highest revenue forecast at $15,191,667,644.